Lysipressin acetate
(Synonyms: 赖氨加压素醋酸盐,Lysine vasopressin acetate; [Lys8]-Vasopressin acetate) 目录号 : GC64811
Lysipressin acetate is the acetate form of Lysipressin.
Cas No.:83968-49-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Vascular smooth muscle cells (VSMCs) |
|
Preparation Method |
VSMCs were isolated from rat aorta and from human uterine artery. hVSMC cells were pre-incubated 20 min at 37 °C in the presence of LiCl (2.10-2 M) with the protease inhibitor Bestatin (10-5 M) and BSA (0.1%), conditions known to reduce peptide degradation and thus terlipressin conversion into Lysipressin. Cells were further incubated in the same media for 2 or 30 additional min in the presence of terlipressin (10-5 M), Lysipressin (10-6 M) or with vehicle (control). |
|
Reaction Conditions |
10-6 M, 2 or 30 min |
|
Applications |
In the presence of protease inhibitors (bestatin and BSA) used to prevent terlipressin conversion into Lysipressin, no significant changes were observed for a short incubation-period (2 min) in either terlipressin or Lysipressin IPs accumulation. After a 30 min incubation period, terlipressin-induced accumulation of IPs was reduced in the presence of BSA and bestatin, but not suppressed. |
|
References: [1]. Colson P H, Virsolvy A, Gaudard P, et al. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: implications for its safety profile[J]. Pharmacological Research, 2016, 113: 257-264. |
|
Lysipressin acetate is the acetate form of Lysipressin. Lysipressin is a nine-amino-acid peptide, which consists of a six-component loop formed by a disulfide bridge, two cysteine residues, and a side chain that includes three amino acid residues. Lysipressin is synthesized in the large cell nuclei of the anterior hypothalamus, stored in the posterior pituitary (neurohypophysis), and secreted into the blood. Depending on the amino acid in the 8th position (lysine or arginine), there are two forms of vasopressin: Lysipressin (lysine vasopressin) or arginine vasopressin [1].
Lysipressin acetate is an arginine vasopressin receptor 1A (V1A) receptor agonist that binds to rat and human V1A receptors (Kis = 1.2 and 10.1 nM, respectively) and Lysipressin acetate increases intracellular calcium levels in cultured rat and human aortic cells with half-maximal activation (Kact) values of 12 and 20.8 nM, respectively. On human cultured VSMCs, LVP and AVP dose-dependently stimulated PLC activity. AVP and LVP both induced dose-dependent and transient increase in [Ca2+]i in rat and human cultured VSMCs [2].
Lysipressin (Lysine vasopressin) is about 1/6 times as potent as Arginine vasopressin in inhibiting water diuresis in dogs when they are injected intravenously in equal vasopressor doses [3]. Lysipressin produce antidiuresis in the pig, without significantly altering glomerular filtration rate [3].
References:
[1]. Grigorjeva M E, Golubeva M G. The Role of Cholinergic Receptors in the Reactions of the Hemostasis System on Vasopressin[J]. Biology Bulletin Reviews, 2022, 12(6): 631-637.
[2]. Colson P H, Virsolvy A, Gaudard P, et al. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: implications for its safety profile[J]. Pharmacological Research, 2016, 113: 257-264.
[3]. MUNSICK R A, SAWYER W H, Van Dyke H B. The antidiuretic potency of arginine and lysine vasopressins in the pig with observations on porcine renal function[J]. Endocrinology, 1958, 63(5): 688-693.
| Cas No. | 83968-49-4 | SDF | Download SDF |
| 别名 | 赖氨加压素醋酸盐,Lysine vasopressin acetate; [Lys8]-Vasopressin acetate | ||
| 分子式 | C48H69N13O14S2 | 分子量 | 1116.27 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.8958 mL | 4.4792 mL | 8.9584 mL |
| 5 mM | 0.1792 mL | 0.8958 mL | 1.7917 mL |
| 10 mM | 0.0896 mL | 0.4479 mL | 0.8958 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。